VECTIBIX 100 MG / 5 ML
PANITUMUMAB : 100 MG / 5 ML · DIN 02308487 · AMGEN CANADA INC
Health Canada status: MARKETED
What is VECTIBIX?
VECTIBIX 100 MG / 5 ML contains PANITUMUMAB : 100 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02308487, held by AMGEN CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 27-May-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VECTIBIX used for?
Treatment of non-mutated (wild-type) RAS metastatic colorectal carcinoma (mCRC) in combination with FOLFOX (first-line) or as monotherapy after chemotherapy failure.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02308487 |
|---|---|
| Brand name | VECTIBIX |
| Generic / active ingredient | PANITUMUMAB : 100 MG / 5 ML |
| Manufacturer | AMGEN CANADA INC |
| Strength | 100 MG / 5 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01FE02 PANITUMUMAB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 27-May-2008 |
| Original market date | 2008-05-27 00:00:00 |
How is it administered?
6 mg/kg IV infusion over 60 minutes once every 2 weeks. Dose modifications required for infusion reactions or grade 3+ dermatological toxicities.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store vials in the refrigerator at 2° to 8°C (36° to 46°F). Do not freeze. Store in the original carton to protect from light.
How is it supplied?
Single-use vials of 100 mg (5 mL) or 400 mg (20 mL) in a dispensing pack containing one vial.
Contraindications
Severe or life-threatening hypersensitivity to panitumumab; patients with RAS mutant mCRC or for whom RAS mutation status is unknown.
Warnings and precautions
Serious dermatologic/soft tissue toxicity (SJS/TEN reported); severe infusion reactions; pulmonary fibrosis/ILD; electrolyte imbalances (hypomagnesemia); ocular toxicities (keratitis).
What can be used instead?
Other Canadian products sharing ATC code L01FE02 PANITUMUMAB. 2 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| VECTIBIX | 400 MG / 20 ML | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02308509 |
| VECTIBIX | 200 MG / 10 ML | SOLUTION | AMGEN CANADA INC | APPROVED | DIN 02308495 |
Who else supplies PANITUMUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PANITUMUMAB appears in 17 registered pack listings across 10 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.